scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

Quality Improvement Grants to improve the early suspicion, identification, and the management of patients with ATTR-CM (Canada)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.
Logo of scientifyRESEARCH + logo of Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The Quality Improvement Grants to improve the early suspicion, identification, and the management of patients with ATTR-CM from Pfizer supports healthcare professionals in Canada on Quality Improvement (QI) initiatives to increase the capacity of the health care system to provide more timely suspicion, identification and diagnosis and appropriate treatment for Transthyretin Cardiac Amyloidosis (ATTR-CM) patients.

Applicants must be based in Canada. The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement. Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged.

The funding provides up to 50,000 CAN including direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Applications close on May 31, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
scientifyRESEARCH
monthly funding newsletter

unsubscribe at any time